Publications

273 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder

Zorginstituut Nederland has completed its assessment whether esketamine nasal spray (Spravato®) can be included in the insured ...

Report | 30-09-2020

Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage

Zorginstituut Nederland has completed its assessment whether trastuzumab-emtansine (Kadcyla®) can be included in the insured ...

Report | 24-09-2020

Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients

Zorginstituut Nederland has completed its assessment whether Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) can be ...

Report | 24-09-2020

Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years and older

Zorginstituut Nederland has completed its assessment whether indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) can ...

Report | 24-09-2020

Osimertinib (Tagrisso®) for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) with an epidermal growth factor receptor (EGFR) mutation (reassessment)

The Minister of Medical Care has requested Zorginstituut Nederland to reassess whether osimertinib (Tagrisso®) for the treatment ...

Report | 21-09-2020

Avelumab (Bavencio®) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma

Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) in combination with axitinib can be included in ...

Report | 21-09-2020

Conditional inclusion procedure for medicinal products

This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.

Publication | 30-07-2020

Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease

Zorginstituut Nederland has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult patients with ...

Report | 03-07-2020

Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

Zorginstituut Nederland has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult patients with ...

Report | 03-07-2020

International strategic agenda 2020 National Health Care Institute

When performing its tasks, the National Health Care Institute (Zorginstituut Nederland, or ZIN) participates with various other ...

Publication | 30-05-2020